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Abstract 
There is an ever-growing need for molecular biomarkers in assessing clinical course and diagnosing neuromuscular disorders, 
as well as in monitoring drug therapy. With the development of high throughput techniques, there has been an acceleration in 
the discovery of potential biomarkers. It is quite easy to find potential candidates, but difficult to validate them and translate 
into a clinical setting. Neuromuscular diseases (NMD) are a major challenge in terms of finding potential molecular biomarkers, 
mainly because of their heterogeneous aetiology and variability in phenotype, their as yet incompletely understood pathop-
hysiology, and their slow clinical progression. Furthermore, it is challenging to assemble a large cohort of patients, as many 
NMDs are rare diseases. 
In this literature review, we provide an update on the latest discoveries in DNA, RNA, miRNA, epigenetic, protein, metabolic and 
cellular biomarkers for NMD. The advantages and potential difficulties of clinical application and the role of identification of 
biomarker panels are discussed. We have especially sought to highlight translational biomarkers which can be easily transferred 
to the clinic, where they may eventually present possible future therapies related to molecular biomarker discoveries. 
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Introduction
In the field of NMD (neuromuscular disorders) there is an 
ever-increasing need for new molecular biomarkers. The di-
scovery of new biomarkers is essential, not only for diagnostic 
purposes, but also to help monitor disease course in clinical 
trials and changes in treatment. This type of biomarker, known 
as a pharmacodynamic biomarker, can indicate e.g. if a protein 
is restored in the course of treatment. Innovative therapeutic 
trials, which tend to be shorter and not always impact pheno-
type, require efficient biomarkers. Some molecular biomarkers 
can even replace functional outcome measures in clinical trials 
and therapy, i.e. surrogate biomarkers. 
A good example of such a surrogate biomarker is dystrop-
hin increase in skeletal muscle during therapy with eteplirsen 
[1]. In this case, an effective biomarker enabled accelerated 
approval by the United States FDA (Food and Drug Admini-
stration). However, despite much effort and countless deve-
lopments in this field, finding a biomarker suitable for clinical 
use remains a challenge. The development of high throughput 
technologies such as NGS (next generation sequencing) and 
omic technologies for proteins have significantly speeded  up 
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the process of screening for molecular biomarkers, but have also 
at the same time created problems related to the interpretation 
of large amounts of data. As screening usually reveals multiple 
potential candidates, it is likely that only a few will prove to be 
effective in the course of clinical validation, which is demand-
ing, time-consuming, and expensive. The application of a panel 
of molecular biomarkers may also be recommended in some 
cases. Furthermore, large clinical studies led by international 
consortia allow for surveys to be carried out on a large cohort 
of patients, something of great importance when dealing with 
rare diseases. In this article, we discuss recent advances in the 
field of molecular biomarkers for NMDs, analyse approaches 
to testing, and review the possible development directions and 
clinical applications in this field.
Criteria for useful biomarkers in NMD
According to the NIH (National Institutes of Health), 
a biomarker is defined as a “characteristic that is objectively 
measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic response 
to a therapeutic intervention” [2]. The most important cha-
racteristics of biomarkers for NMD are: 
 — analytical validity (the ability to accurately distinguish 
between normal and altered status as well as treatment 
response/non-response), 
 — clinical validity (the ability to reflect the features of the 
disease), 
 — non-invasiveness, 
 — feasibility (how simple it is to measure), 
 — cost-effectiveness (being quick and easy to use) [3]. 
According to the FDA, an ideal biomarker must be spe-
cifically associated with a particular disease or disease state, 
and be able to differentiate between similar physiological con-
ditions [4–5]. Biomarkers should also correlate with clinical 
outcomes and radiological measures. In terms of accessibility, 
an ideal biomarker would be easily accessible e.g. from plasma 
[6]. However, due to the tissue-specific expression of a number 
of proteins, biomarkers from muscle and skin biopsies still play 
an important role. CK is still widely used as a biomarker in 
NMD despite its limitations (it is neither a specific nor a sens-
itive marker for neuromuscular disease). Reliable biomarkers 
for NMD in urine or saliva have yet to be identified. In this 
article, we will differentiate between seven types of biomarkers: 
 — diagnostic – to detect or confirm the presence of a disease 
or condition of interest, or identify an individual with 
a subtype of the disease, 
 — monitoring – to assess the status of a disease or to detect 
the effect of a medical product or biological agent, 
 — pharmacodynamic response - changes in response to 
exposure to a medical product, 
 — predictive – its presence or change predicts whether an 
individual will experience an effect from the exposure to 
a medical product, 
 — prognostic - identifies the likelihood of a clinical event 
in an individual, 
 — safety - indicates the likelihood, presence, or extent of 
a toxicity 
 — susceptibility/risk biomarkers – indicates potential for 
developing a disease in a healthy individual [7]. 
A surrogate biomarker is defined as ‘a biomarker inten-
ded to substitute for a clinical endpoint’. Biomarkers used as 
an endpoint are often easier to assess and more cost efficient 
than clinical biomarkers. Translational biomarkers can be 
easily transferred between pre-clinical and clinical research.
Neuromuscular disorders
NMDs are heterogeneous groups of neurological diseases, 
including both myopathies as well as neuropathies. The term 
encompasses various conditions with a different pathophy-
siological and genetic aetiology, distinct pathophysiological 
pattern, and heterogeneous phenotypes, even within one 
disease [8]. There are 955 neuromuscular diseases associated 
with 535 different genes [9]. They affect directly, by causing 
pathology in a muscle, or indirectly, by affecting a neuromu-
scular junction or nerves. The onset varies from infancy to 
late adulthood. The most common symptoms include muscle 
weakness that can lead to twitching, cramps and pains, muscle 
atrophy and hypertrophy, ptosis, swallowing problems, ske-
letal deformities, fatigability, a waddling gait, and respiratory 
and cardiac dysfunction. In this article we will concentrate 
on muscular dystrophy (DMD, BMD), limb girdle muscular 
dystrophy (LGMD), amyotrophic lateral sclerosis (ALS), 
facioscapulohumeral muscular dystrophy (FSHD), Charcot-
-Marie-Tooth disease (CMT), spinal muscle atrophy (SMA), 
dystrophic myotonias (DM1 and DM2) and Pompe disease 
(MP). As some of these neuromuscular diseases are very rare, 
one of the main obstacles to discovering potential molecular 
biomarkers is the scarcity of samples. Rare neuromuscular 
conditions can often remain undiagnosed, which significantly 
impacts upon care.
Molecular biomarkers
We classified the biomarkers based on their chemical 
structure into: 
 — DNA 
 — RNA (including miRNA) 
 — proteins and peptides 
 — others (metabolic, cellular) [10]. 
The main advantages and disadvantages of each class of 
biomarker are set out in Table 1.
Genomic biomarkers
RNA, and DNA and DNA epigenetic modifications en-
compass a larger class of genomic biomarkers.
175www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Magdalena Mroczek et al., Molecular biomarkers for neuromuscular disorders
 DNA
DNA biomarkers include SNP (single polymorphism vari-
ant) and CNV (copy number variant) as well as insertions, 
deletions and translocations. DNA biomarkers are easily ac-
cessible and repeatable, but their functional meaning is often 
difficult to assess. Next generation sequencing (NGS) has 
enabled the rapid discovery of new genes in one-gene disorders 
and genetic modifiers due to the possibility of finding statistical 
correlations between phenotypes and genetic variants. 
SNP
A single-nucleotide polymorphism (SNP), which is a varia-
tion in a single nucleotide that occurs at a specific position in 
the genome, is a promising alternative biomarker. DMD is one 
of the neuromuscular conditions most often screened for SNP 
biomarkers, mainly because of the range of phenotypes among 
individuals who carry the same mutation. Several indepen-
dent studies have identified genetic diagnostic and prognostic 
biomarkers belonging to pathways involved in inflammation, 
muscle regeneration and contraction (TGF-β), calcium ho-
meostasis, fibrosis and macrophage infiltration (Cd68) and 
genetic modifiers (SPP1) [11]. Large studies, with more than 
200 DMD patients enrolled, have shown that the following 
variants: V194I, T787A, T820A, and T1140M, form the VTTT 
and IAAM in LTBP4 haplotypes. LTBP4 encoding TGF-beta-
-binding protein acts as a genetic modifier. Steroid-treated 
DMD patients homozygous for IAAM remained ambulatory 
significantly longer (up to 12.5 ± 3.3 years) than similarly 
treated individuals heterozygotes or homozygotes for VTTT 
(ambulatory up to 10.7 ± 2.1 years under treatment) [12–13]. 
Another candidate biomarker for DMD is osteopontin 
(SPP1). SPP1 expression has been found to be downregu-
lated approximately three-fold in DMD patients with a mild 
phenotype compared to those who are severely affected. SNP 
−66T>G in the promoter region of SPP1 correlates with greater 
DMD phenotype severity [14]. SMN2, PLS3 and ZPR1 were 
rated as modifiers for SMN2 and EPHA4 and SMN for ALS. 
The modifier effect is not yet fully understood, and further stud-
ies are needed [15]. Four single nucleotide SNPs in SIPA1L2 were 
recently proved to correlate with foot dorsiflexion strength in 
Charcot-Marie-Tooth patients. This study was performed on 
more than 300 patients using genome-wide methods [16].
CNV
Another very promising alternative biomarker is a copy 
number variation (CNV). This refers to the structural varia-
tions – individually variable repeats in the genome. They have 
already found their diagnostic application in diseases such as 
CMT1A with PMP22 duplication and SMA with SMN1 dupli-
cation [17]. Some smaller studies regarding CMT showed that 
neuropathy-associated CNVs outside of the PMP22 locus are 
rare [18]. In ALS, EPHA3 deletion was defined as a potential 
protective factor (prognostic and monitoring biomarker), but 
here again the data was gathered only in a small study [19]. 
There are ongoing works for validating potential modifying 
CNVs in the SD region of TTN and the TRI region of NEB [20]. 
One big biomarker study failed to identify CNV biomarkers 
in DMD and COL6 myopathies [21].
Epigenetic biomarkers
Epigenetics is a heritable and acquired alteration in gene 
activity and expression via chromatin reorganisation without 
changes in DNA sequence. Epigenetic alterations can occur 
even in the differentiated cells in response to external fac-
tors. Examples of epigenetic changes are DNA methylation 
and histone modifications. FSHD is a neuromuscular disease 
associated with an impaired methylation pattern. FSHD is 
caused by a reduction in the number of 3.3 kb D4Z4 units 
arrayed on chromosome 4 to fewer than 11 units. This epi-
genetic pattern results in transcription of the DUX4, which 
is normally repressed, but only in patients with permissive 
D4Z4 haplotypes. The latest research indicates that other fac-
tors may be involved in DUX4 repression and may therefore act 
as biomarkers [22]. These are PRC2 as the complex primarily 
responsible for DUX4 repression in FSHD, and H3K9 acety-
lation along with loss of H3K27me3 as key epigenetic events 
that result in DUX4 expression [23]. Other examples of the 
NMD with impaired epigenetics pattern are Emery-Dreifuss 
muscular dystrophy (EDMD) and progeria. It is still not fully 
understood how the disease can manifest with two extremely 
diverse phenotypes. A decrease of the heterochromatin mark 
H3K9me3 in pericentric regions and a downregulation of the 
PRC2 may act as a modifier and may be regarded as a prog-
nostic biomarker in assessing the course of the disease [24].
RNA
RNA, and particularly miRNA, has been investigated 
as a biomarker in multiple recent studies. Measuring RNA as 
biomarkers is effective, as RNA provides the most direct route 
for biomarker validation and assay development. A significant 
bottleneck in advancing RNA biomarker discoveries to the 
clinic is the lack of standardised and robust technologies for 
Table 1. Advantages and disadvantages of DNA, RNA and protein biomarkers
Type of  
biomarker
Advantages Disadvantages




and discovery process 
Difficulties with data 
interpretation
RNA Tissue specificity Low stability 
Low accessibility
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measuring RNA biomarkers in situ in clinical specimens, not to 
mention the fact that RNA is unstable and not easily accessible.
mRNA
The possibility of whole transcriptome analysis has con-
tributed greatly to the diagnosis and discovery of RNA ex-
pression patterns in numerous NMDs. The limitation is the 
tissue-specificity of RNA.
In DM, aberrant alternative splicing plays a key role in the 
pathogenesis. The timing of the appearance of certain miss-
-spliced events correlates well with disease severity [25]. Ho-
wever, there is not always a direct link between phenotype and 
RNA level. An SMA study (copy variant dependent disease) 
surprisingly did not show a clear correlation between SMN 
RNA expression and motor function [26]. In hereditary neu-
ropathies, recent studies have proved a correlation with several 
RNA biomarkers from skin biopsies (which can be regarded as 
prognostic and monitoring biomarkers): PARG, GSTT2, CTSA, 
CDA, ENPP1 and NRG1 in different metabolic pathways with 
disease progression over time [27]. One analysis addressing 
whole transcriptome in ALS detected more than 2,000 diffe-
rentially expressed transcripts in whole blood transcriptome 
among nearly 400 ALS patients and a large group of healthy 
individuals. Nevertheless, data interpretation is challenging 
[28]. Whole transcriptome analysis of a DMD animal model 
showed different expression patterns in a substantial number of 
genes. A major obstacle to this study is data interpretation [29]. 
Non-coding RNA
In recent years, high throughput technologies have enabled 
an outline of how non- coding RNAs play a regulatory role, 
providing a potential biomarker for NMD.
miRNAs are non-coding nucleic acids which target mRNA. 
They are relatively stable and have high concentrations in the 
blood and the cerebrospinal fluid (CSF). MiRNAs are espe-
cially attractive as biomarkers because of their potential utility 
in experimental therapy, as some of them correlate with the-
rapeutic outcomes. Several microRNAs showed dysregulated 
expression levels in NMD [30]. miR-1, miR-133a, and miR-
206 can be used as powerful prognostic serum biomarkers, 
not only in DMD but also in myotonic dystrophy 1 (DM1), 
limb-girdle muscular dystrophy (LGMD), facioscapulohume-
ral muscular dystrophy (FSHD), Becker muscular dystrophy 
(BMD), and distal myopathy with rimmed vacuoles (DMRV). 
DMD is probably the most-investigated NMD in terms of 
miRNA. Not only three different miRNAs, also known as 
myomiRs (miR-1, miR-133a/b, and miR-206), showed incre-
ased expression in DMD, but also others, such as: miR-208b, 
miR-499 and miR-31, were overexpressed in DMD patients 
[31–32]. Studies with phosphorodiamidate morpholino oligo-
nucleotide (PMO)-mediated dystrophin restoration therapy in 
mdx mice (animal model of DMD) showed the ability of the 
therapy to correct the dysregulation of the myomiRs (miR-1, 
-133a/b, -206) to normal wild type levels in serum [33]. These 
are especially attractive as potential surrogate biomarkers. 
Serum levels of miRNAs: miR-206, 143-3p and 374b-5p could 
differentiate a patient with ALS from healthy controls and 
from patients with other, similar, neuromuscular diseases 
[34]. MiR‐9, miR‐132, miR‐206, miR‐183 and miR‐375 were 
identified as prospective biomarkers for SMA [35]. miR-133a 
was increased in patients with Pompe disease in a study of 
52 patients, while in three newborns miR-133a decreased after 
starting a replacement therapy [36].
Piwi-interacting RNAs have only recently been linked 
to human diseases. piRNAs are of interest because they have 
established gene regulatory functions. Specific serum piRNAs 
also responded to exon skipping therapy. The role of Piwi-
-interacting RNAs needs further investigation [37].
Proteins and peptides
Proteomic biomarkers have rapidly developed in recent 
years, mainly because of the introduction of new discovery 
techniques. Thanks to mass spectrometry (MS)-based pro-
teome profiling and affinity multiplexing assays, candidate 
proteins and peptide biomarkers can be identified faster and 
more effectively [38]. Protein and peptide biomarkers are easily 
accessible and relatively cost effective to test. Their limitations 
are instability and problems with repeatability.
CK
A protein diagnostic biomarker still widely used in clinical 
practice is creatinine kinase-M (CK-M). This is a diagnostic 
biomarker of muscle (sarcolemma) damage. CK can be applied 
as a screening parameter for NMD, but it does not correlate 
well with disease progression and treatment, and shows va-
riability among individuals. 
NfL as marker of nerve damage
Neurofilament is a major cytoskeletal protein, expressed 
in both CNS and PNS, which increases during neuronal 
damage both in the blood and in the CSF. It is composed of 
neurofilament light (NFL), medium (NFM), and heavy (NFH) 
chains. NfL is elevated in multiple neurodegenerative disor-
ders, including Alzheimer’s disease, multiple sclerosis, and 
frontotemporal dementia. A 20-year study revealed that NfL 
can be a reliable biomarker for ALS, particularly when mea-
sured in CSF [39]. Some recent studies have shown that NfL 
may find its application as a prognostic biomarker for CMT. 
NfL tested in the blood of patients with CMT was increased 
compared to healthy controls. This biomarker correlated with 
clinical disease severity assessed with Rasch modified CMT 
examination and neuropathy scores [40]. 
Candidate protein biomarkers
Recent studies, based on multi omics techniques, have 
identified multiple potential protein biomarkers, but very few 
of them have found an application in clinics. DMD is of great 
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interest regarding serum protein biomarkers. As potential 
candidates, the following proteins have been identified: car-
bonic anhydrase III (CA-III), MMP9, TIMP1, osteopontin, 
amyoglobin, myosin light chain-3 (MYL3), troponin T, fast 
skeletal muscle (TNNT3), plastin-2 (LCP1), protein phospha-
tase 1F (PPM1F) and electron transfer flavoprotein A (ETFA) 
[41–43]. They are tied to different pathobiochemical pathways 
indicative of muscle fibre leakage, inflammation, fibrosis and 
muscle degeneration/regeneration. MMP-9, a serum marker of 
degradation and remodelling of the extracellular matrix, was 
identified a few years ago as one of the most suitable serum 
biomarkers to monitor disease progression and therapy in 
DMD [44]. MMP-9 is not specific for DMD and is also elevated 
in patients with Bethlem and Ullrich myopathy compared to 
controls. The rise in MMP-9 levels in COL6-related myopathies 
was less pronounced than in DMD and BMD. Recent studies 
have revealed that MMP-9 is not a reliable marker to monitor 
disease course in antisense therapy of DMD [45]. High throu-
ghput technologies have highlighted myomesin 3 (MYOM3) 
as a potential proteomic biomarker, which correlates well 
with clinical course of both LGMD and DMD. MYOM3 is 
a myofibrillar structural protein, present in the sera of DMD 
and LGMD2D patients, as well as in their respective animal 
models [46]. No powerful candidate biomarker has been 
identified in the sera of patients with SMA: there was a trend 
correlation with clinical symptoms for a few candidates, but 
statistical significance was not reached [47, 48]. Some recent 
studies have indicated exosome-derived SMN protein as a pro-
mising biomarker for SMA [48]. For LGMD, troponin I (sTnI), 
myosin light chain 3 (Myl3) and fatty acid binding protein 
3 (FABP3) have been proposed as potential protein serum 
biomarkers. These proteins reached statistical significance 
with some clinical endpoints [49]. In CMT patients, a decrease 
of some mitochondrial proteins in skin biopsies was noticed 
[50]. In a small study of CMT patients, several biomarkers 
were identified, including alterations to serum amyloid pro-
tein specific for CMT1 patients and serum transferrin. These 
results should be verified on a larger cohort of patients [52]. 
In ALS patients, the most promising protein biomarkers are 
p75 neurotrophin domain and neurofilaments subunit proteins 
(NfH and NfL). All these markers are released by neuron or 
Schwann cell injury and they are not specific for ALS only. p75, 
which regulates growth and cell differentiation, is high after 
birth, then decreases in later life and is released to the CSF 
by Schwann cell or axonal damage. p75 is also elevated in the 
urine of affected individuals and model animals, and increases 
with disease progression [53]. Another discussed candidate is 
one of the growth factors - progranulin (PGRN), which rises 
in CSF as ALS progresses (monitoring biomarker) [54].
Other biomarkers
Metabolites – These are the intermediate end product of 
metabolism and are usually various types of small molecules. 
A new metabolomics technology to study data from a large 
number of metabolites at the same time is called metabolo-
mics [55]. For NMD there are only a few known metabolic 
biomarkers, as they are not always useful in this application. 
Prostaglandin D2 metabolite is increased in DMD patients 
compared to healthy controls [56]. Other studies have shown 
increased lipid profile and L-arginine/nitric oxide pathway 
imbalance in DMD patients [57, 58]. In omni metabolomics 
analysis, IBM (inclusion body miosities) and mitochondrial 
neuromuscular diseases clustered differently from other 
NMDs. Sorbitol, alanine, myoinositol, and cystathionine 
have been proposed as candidate metabolite biomarkers for 
mitochondrial myopathies [59].
Cellular biomarkers – for collagen disease in Bethlem 
myopathy and Ullrich myopathy, the infiltration of macrop-
hages can serve as a biomarker. A difference between DMD 
Table 2. Promising biomarkers for NMD in terms of possible clinical application
Biomarker Disease Chemical class Comment
CK NMD protein Not useful in monitoring disease course; great inter-individual variability
LTBP4 DMD SNP Haplotypes well characterised in a relatively large cohort of DMD patients
SPP1 DMD SNP Correlates well with time of ambulation loss
miR-1, -133a/b, -206 DMD miRNA Correlates with treatment outcomes
miR-133a Pompe disease miRNA Assessed in a large cohort of patients afflicted with Pompe disease
NfL ALS, CMT protein Large and long term studies on ALS patients; correlates well with ALS 
course especially when measured in CSF 
PGRN ALS protein
MMM-9 DMD protein Not suitable for monitor splicing therapy
Troponin I (sTnI), myosin light 
chain 3 (Myl3) and fatty acid 
binding protein 3 (FABP3)
LGMD protein Apart from LGMD expressed also in DMD, BMD, but presents a different 
pattern
Serum amyloid protein and 
serum transferrin
CMT protein Serum amyloid protein is specific to CMT genetic type
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and healthy controls can be tested with a flow cytometer. In 
the case of SMA, the expression of SMN protein in CD3+, 
CD19+, and CD33++ cells from SMA patients was significantly 
reduced compared to that in cells from control subjects [60].
Conclusion
Future directions and clinical implications. High-throu-
ghput technologies have enabled fast screening for candidate 
biomarkers, but clinical validation remains a challenge. 
The integration of molecular biomarkers with clinical end-
points and MRI biomarkers is needed. In some cases, a panel 
of biomarkers can be much more sensitive than one. Because 
many NMDs are rare, the omics databases should be ava-
ilable for the researcher community. Another challenge is 
the interpretation of big data produced in high-throughput 
technologies and establishing a reliable pattern of biomarkers 
expression in healthy and affected individuals. Novel biomar-
kers such as miRNA and protein biomarkers open new therapy 
perspectives as they can correlate with disease course. A few 
attractive potential biomarkers have already been outlined, 
and their advantages and limitations are set out in Table 2. 
Many of them were investigated only in small studies, and 
validation on a larger cohort of patients is required. Due to 
the discovery of candidate biomarkers, molecular pathogenesis 
of NMDs is better understood and potential targets for future 
therapies can be identified. Some candidates are attractive 
options for surrogate biomarkers in future clinical trials. This 
could significantly speed up trials, thus making them more 
affordable. The efforts to deliver reliable and sensitive biomar-
kers have intensified in recent years. We hope that some of the 
achievements from basic science and pre-clinical trials can be 
successfully translated into clinical practice.
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